SCHEMBL20914481

SCHEMBL20914481

COC(=O)c1ccccc1-c1cccc(Cn2cccn2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.53
TSHR P16473 1/20 0.53
KMT2A Q03164 1/20 0.53
HTT P42858 2/20 0.51
SLC6A3 Q01959 4/20 0.47
SLC6A4 P31645 3/20 0.47
SLC6A2 P23975 1/20 0.47
AGTR1 P30556 1/20 0.47
AGTR2 P50052 1/20 0.47
ALOX15 P16050 1/20 0.47
HSD17B10 Q99714 1/20 0.47
USP2 O75604 1/20 0.46
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.46
GRK6 P43250 1/20 0.45
GRM5 P41594 1/20 0.45
PRKACA P17612 1/20 0.45
PRKACG P22612 1/20 0.45
PRKACB P22694 1/20 0.45
KAT7 O95251 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30284989 1.00 MEN1 (0.53) MEN1TSHRKMT2AHTTSLC6A3
SCHEMBL19512698 0.91 AGTR1 (0.48) MEN1TSHRKMT2AHTTSLC6A3
SCHEMBL17992347 0.85 GRM5 (0.47) SLC6A3SLC6A4SLC6A2AGTR1AGTR2
SCHEMBL14987126 0.79 HTT (0.71) MEN1TSHRKMT2AHTTALOX15
SCHEMBL30285026 0.79 SLC6A3 (0.50) KMT2ASLC6A3SLC6A4SLC6A2AGTR1
SCHEMBL19475034 0.79 SLC6A3 (0.50) KMT2ASLC6A3SLC6A4SLC6A2AGTR1
SCHEMBL31172538 0.79 HTT (0.52) MEN1TSHRKMT2AHTTALOX15
SCHEMBL22071077 0.78 SLC6A3 (0.58) KMT2ASLC6A3SLC6A4SLC6A2GAA
SCHEMBL30285311 0.77 SLC6A3 (0.50) KMT2ASLC6A3SLC6A4SLC6A2AGTR1
SCHEMBL19512901 0.77 SLC6A3 (0.50) KMT2ASLC6A3SLC6A4SLC6A2AGTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109311813-B Palladium-catalyzed meta-C-H functionalized universal ligands 斯克利普斯研究院 2023-02-28 CN disclosed
US-10696635-B2 Versatile ligand for palladium-catalyzed meta-C—H functionalizations of aromatic substrates THE SCRIPPS RESEARCH INSTITUTE (US) 2020-06-30 US disclosed
US-10696635-B2 Versatile ligand for palladium-catalyzed meta-C—H functionalizations of aromatic substrates THE SCRIPPS RESEARCH INSTITUTE (US) 2020-06-30 US disclosed
US-20190119212-A1 A VERSATILE LIGAND FOR PALLADIUM-CATALYZED META-C-H FUNCTIONALIZATIONS THE SCRIPPS RESEARCH INSTITUTE 2019-04-25 US disclosed
US-20190119212-A1 A VERSATILE LIGAND FOR PALLADIUM-CATALYZED META-C-H FUNCTIONALIZATIONS THE SCRIPPS RESEARCH INSTITUTE 2019-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119212-A1 A VERSATILE LIGAND FOR PALLADIUM-CATALYZED META-C-H FUNCTIONALIZATIONS AHR, PAH, DOHH MEN1 1353/4885TSHR 250/4885KMT2A 1557/4885
US-10696635-B2 Versatile ligand for palladium-catalyzed meta-C—H functionalizations of aromatic substrates PAH, AHR, DDC MEN1 1194/4885TSHR 408/4885KMT2A 1517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.